Cargando…
Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report
BACKGROUND: Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor administered to patients with chronic myelogenous leukemia and gastrointestinal stromal tumor. Although imatinib-associated interstitial lung disease is uncommon, a few cases have been reported so far. However, in...
Autores principales: | Nakashima, Shota, Kakugawa, Tomoyuki, Motomura, Hiroko, Hirano, Katsuji, Sasaki, Eisuke, Nagata, Yasuhiro, Kinoshita, Akitoshi, Sakamoto, Noriho, Ishimatsu, Yuji, Mukae, Hiroshi, Kohno, Shigeru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537559/ https://www.ncbi.nlm.nih.gov/pubmed/23174134 http://dx.doi.org/10.1186/2049-6958-7-48 |
Ejemplares similares
-
Serum heat shock protein 47 levels are elevated in acute interstitial pneumonia
por: Kakugawa, Tomoyuki, et al.
Publicado: (2014) -
Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis
por: Sakamoto, Noriho, et al.
Publicado: (2015) -
Serum heat shock protein 47 levels in patients with drug-induced lung disease
por: Kakugawa, Tomoyuki, et al.
Publicado: (2013) -
High serum concentrations of autoantibodies to HSP47 in nonspecific interstitial pneumonia compared with idiopathic pulmonary fibrosis
por: Kakugawa, Tomoyuki, et al.
Publicado: (2008) -
Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
por: Sakamoto, Noriho, et al.
Publicado: (2018)